{"id":"placebo-of-warfarin","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1464","moleculeType":"Small molecule","molecularWeight":"308.33"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Placebos are inert substances used as controls in clinical trials to measure the effect of patient expectation and the natural disease course independent of active drug treatment. In this Phase 3 trial context, the placebo serves as a comparator arm against warfarin, a vitamin K antagonist anticoagulant. Any observed effects in the placebo group reflect the placebo effect, regression to the mean, and natural disease progression rather than direct molecular action.","oneSentence":"A placebo has no active pharmacological mechanism; it produces therapeutic effects solely through psychological and physiological expectation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:13.522Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in warfarin efficacy and safety trial (indication under investigation)"}]},"trialDetails":[{"nctId":"NCT06025552","phase":"PHASE1","title":"Study of TU7710 in Warfarin Anti-coagulated Healthy Male Subjects","status":"COMPLETED","sponsor":"TiumBio Co., Ltd.","startDate":"2023-08-02","conditions":"Hemophilia a, Hemophilia B, Blood Coagulation Disorders","enrollment":40},{"nctId":"NCT06615596","phase":"EARLY_PHASE1","title":"Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2025-01","conditions":"Atrial Fibrillation (AF)","enrollment":3160},{"nctId":"NCT04730037","phase":"PHASE3","title":"Clinical Trial to Investigate Safety and Efficacy of Edoxaban in Patients With CTEPH (KABUKI)","status":"COMPLETED","sponsor":"Kyushu University","startDate":"2021-03-23","conditions":"CTEPH","enrollment":74},{"nctId":"NCT01017666","phase":"PHASE1","title":"BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Midazolam","status":"COMPLETED","sponsor":"Biogen","startDate":"2009-11-01","conditions":"Healthy","enrollment":28},{"nctId":"NCT02836652","phase":"PHASE4","title":"Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2016-11","conditions":"Heart Failure","enrollment":72},{"nctId":"NCT00432796","phase":"PHASE3","title":"PERIOP 2 - A Safety and Effectiveness of LMWH vs Placebo Bridging Therapy for Patients on Long Term Warfarin Requiring Temporary Interruption of Warfarin.","status":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2006-12","conditions":"Stroke","enrollment":1473},{"nctId":"NCT02070510","phase":"PHASE1","title":"A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-02-27","conditions":"Diabetes, Healthy","enrollment":52},{"nctId":"NCT00781391","phase":"PHASE3","title":"Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2008-11","conditions":"Stroke, Atrial Fibrillation, Embolism","enrollment":21105},{"nctId":"NCT02022254","phase":"PHASE1","title":"Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-12-17","conditions":"Diabetes, Diabetes Mellitus, Type 2, Healthy","enrollment":24},{"nctId":"NCT00740883","phase":"PHASE3","title":"Extended Duration of Oral Anticoagulant Therapy After a First Episode of Idiopathic Pulmonary Embolism: a Randomized Controlled Trial. \"PADIS-PE\" Study.","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2007-07","conditions":"Pulmonary Embolism","enrollment":374},{"nctId":"NCT00740493","phase":"PHASE3","title":"Prolonged Anticoagulation After a First Episod of Idiopathic Proximal Deep Vein Thrombosis (PADIS TVP)","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2007-07","conditions":"Recurrent Venous Thromboembolism, Idiopathic Deep Vein Thrombosis","enrollment":104},{"nctId":"NCT01561937","phase":"PHASE1","title":"Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-01","conditions":"Haemostasis, Healthy","enrollment":127},{"nctId":"NCT01036802","phase":"PHASE2","title":"Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-12","conditions":"Pulmonary Hypertension","enrollment":3},{"nctId":"NCT00345618","phase":"PHASE3","title":"Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Embolism, Thrombosis","enrollment":3202},{"nctId":"NCT00580216","phase":"PHASE3","title":"Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation","status":"TERMINATED","sponsor":"Sanofi","startDate":"2007-12","conditions":"Atrial Fibrillation","enrollment":3773},{"nctId":"NCT00786474","phase":"PHASE3","title":"Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)","status":"COMPLETED","sponsor":"Duke University","startDate":"2009-07","conditions":"Arterial Thromboembolic Events, Atrial Fibrillation","enrollment":1884},{"nctId":"NCT02623296","phase":"PHASE1","title":"A Drug-drug Interaction Study Between GLPG1205 and a Cocktail of CYP450 Substrates in Healthy Male Subjects","status":"COMPLETED","sponsor":"Galapagos NV","startDate":"2015-10","conditions":"Healthy","enrollment":14},{"nctId":"NCT00990158","phase":"PHASE3","title":"Does Low Dose Oral Vitamin K Improve International Normalized Ratio (INR) Stability?","status":"COMPLETED","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2010-07","conditions":"Coagulation, Bleeding, Thrombosis","enrollment":235},{"nctId":"NCT00494871","phase":"PHASE3","title":"Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-06","conditions":"Atrial Fibrillation","enrollment":1280},{"nctId":"NCT00957242","phase":"PHASE3","title":"AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis","status":"TERMINATED","sponsor":"Duke University","startDate":"2009-10","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":145},{"nctId":"NCT00329238","phase":"PHASE3","title":"Secondary Prevention of Venous Thrombo Embolism (VTE).","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-05","conditions":"Thromboembolism","enrollment":2867},{"nctId":"NCT00680186","phase":"PHASE3","title":"Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-04","conditions":"Thromboembolism","enrollment":2589},{"nctId":"NCT00403767","phase":"PHASE3","title":"An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2006-12","conditions":"Atrial Fibrillation, Stroke, Embolism","enrollment":14269},{"nctId":"NCT00643201","phase":"PHASE3","title":"Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-07","conditions":"Venous Thrombosis","enrollment":5614},{"nctId":"NCT00618579","phase":"PHASE1","title":"Effects of LMWH in Healthy Subjects Treated With TB-402 and Effects of TB-402 in Healthy Subjects Treated With Warfarin","status":"COMPLETED","sponsor":"ThromboGenics","startDate":"2008-02","conditions":"Healthy","enrollment":15},{"nctId":"NCT02022527","phase":"PHASE4","title":"Cost Effectiveness Analysis In Patients With Heart Valve Prosthesis","status":"UNKNOWN","sponsor":"Pharmacoeconomic Unit, Egypt","startDate":"2013-06","conditions":"Complications Due to Heart Valve Prosthesis","enrollment":300},{"nctId":"NCT01762891","phase":"NA","title":"CI(R)CA : Coumadin Interaction With Rofecoxib, Celecoxib and Acetaminophen","status":"COMPLETED","sponsor":"Hospital Universitario Pedro Ernesto","startDate":"2003-03","conditions":"Antiphospholipid Antibody Syndrome","enrollment":22},{"nctId":"NCT00621491","phase":"NA","title":"Prevention of Venous Thrombosis After Permanent Transvenous Leads Implantation","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2004-02","conditions":"Cardiac Pacing, Complications, Venous Thrombosis","enrollment":101},{"nctId":"NCT00487136","phase":"PHASE1","title":"Interaction Between ABT-335, Rosuvastatin and Warfarin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-06","conditions":"Healthy","enrollment":45},{"nctId":"NCT00697151","phase":"PHASE4","title":"Patent Foramen Ovale in Cryptogenic Stroke Study","status":"COMPLETED","sponsor":"Columbia University","startDate":"1993-06","conditions":"Ischemic Stroke, Patent Foramen Ovale","enrollment":630},{"nctId":"NCT00794755","phase":"PHASE3","title":"Low Dose Supplementation to Improve Anticoagulation Control With Oral Vitamin K as an Adjuvant to Warfarin Therapy","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2008-11","conditions":"Coagulation","enrollment":100},{"nctId":"NCT01388075","phase":"NA","title":"Genetic Variability in the Response to Warfarin at Baseline and During Induction of CYP2C9","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2011-07","conditions":"Healthy Subjects","enrollment":150},{"nctId":"NCT00027066","phase":"PHASE3","title":"Warfarin Versus Aspirin Recurrent Stroke Study","status":"COMPLETED","sponsor":"Columbia University","startDate":"1993-06","conditions":"Stroke","enrollment":2206},{"nctId":"NCT01095588","phase":"PHASE1","title":"Study the Effect of Avanafil on the Pharmacodynamics and Pharmacokinetics of Warfarin in Healthy Male Subjects","status":"COMPLETED","sponsor":"VIVUS LLC","startDate":"2010-04","conditions":"Erectile Dysfunction","enrollment":24},{"nctId":"NCT01103609","phase":"PHASE1","title":"Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-04","conditions":"Type 2 Diabetes Mellitus","enrollment":16},{"nctId":"NCT01104337","phase":"PHASE4","title":"Drug Interaction Between Paracetamol and Warfarin","status":"COMPLETED","sponsor":"Hopital Lariboisière","startDate":"2007-03","conditions":"Deep Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":45},{"nctId":"NCT00097357","phase":"PHASE2, PHASE3","title":"BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-10","conditions":"Venous Thrombosis, Pulmonary Embolism","enrollment":1238},{"nctId":"NCT00689637","phase":"PHASE1","title":"Drug Interaction Study Between AZD3480 and Warfarin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-09","conditions":"Alzheimer's Disease","enrollment":26},{"nctId":"NCT00157651","phase":"PHASE3","title":"Access II - Trial of Warfarin to Prevent Malfunction of Haemodialysis Catheters","status":"COMPLETED","sponsor":"Hamilton Health Sciences Corporation","startDate":"1999-02","conditions":"End Stage Renal Disease, Thrombosis, Bleeding","enrollment":170}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":214,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"placebo of warfarin","genericName":"placebo of warfarin","companyName":"University Hospital, Brest","companyId":"university-hospital-brest","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo has no active pharmacological mechanism; it produces therapeutic effects solely through psychological and physiological expectation. Used for Control arm in warfarin efficacy and safety trial (indication under investigation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}